TGV-Dx is developing and commercializing a new generation antimicrobial susceptibility test (AST), AtbFinder® - a breakthrough diagnostic platform technology enabling physicians to select the most effective antibiotic regimens (even for hard-to-treat, recurrent infections) with unprecedented speed and accuracy, helping save lives and significantly lowering healthcare costs.
The AtbFinder is based on a proprietary methodology, and is a breakthrough since it is phenotypic (not genetic) but is culture-independent, delivering results from “raw” clinical samples just in 4 hours.
AtbFinder enables the selection of the most efficacious antibiotic therapy for drug-resistant bacterial infections with unprecedented speed and accuracy: (i) results in 4 hours, (ii) each sample is screened through the largest antibiotic menu of 188 drugs.
Unlike any competing AST, AtbFinder works with polymicrobial infections. It is an all-in-one prefabricated kit that does not need any special equipment and does not require a pathogen ID.
AtbFinder is a platform technology used for:
• Urinary Tract infections
• Reparatory tract infections
• Skin and soft tissue infections
Company Details
- Employees
- 1
- Founded
- -
- Address
- 180 Varick St, New York,ny 10014,united States
- Industry
- Medical And Diagnostic Laboratories
- NAICS
-
Medical and Diagnostic LaboratoriesMedical LaboratoriesDiagnostic Imaging Centers
- Website
- https://tgvdx.com/
- Keywords
- Boca Raton.
- HQ
- New York, NY
Tgv-Dx Questions
Tgv-Dx's website is https://tgvdx.com/
Tgv-Dx's LinkedIn profile is https://www.linkedin.com/company/tgv-dx-inc
Tgv-Dx has
1 employees.
View email and phone details for 1
employees at Tgv-Dx.
Tgv-Dx's industry is
Medical and Diagnostic Laboratories
Tgv-Dx's categories are Medical and Diagnostic Laboratories
Tgv-Dx's founding year is 2020
